AR103194A1 - Formas sólidas de un compuesto antiviral - Google Patents
Formas sólidas de un compuesto antiviralInfo
- Publication number
- AR103194A1 AR103194A1 ARP150101835A ARP150101835A AR103194A1 AR 103194 A1 AR103194 A1 AR 103194A1 AR P150101835 A ARP150101835 A AR P150101835A AR P150101835 A ARP150101835 A AR P150101835A AR 103194 A1 AR103194 A1 AR 103194A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- imidazol
- solid forms
- crystalline
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- -1 naphtho [1,2-d] imidazole- 2-yl Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 229910002483 Cu Ka Inorganic materials 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Formas sólidas cristalinas de metilo {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(metoxicarbonilo)amino]-2-fenilacetil}-4-(metoximetilo)pirrolidin-2-il]-1H-imidazol-5-il}-1,11-dihidroisocromeno[4,3:6,7]nafto[1,2-d]imidazol-2-il)-5-metilopirrolidin-1-il]-3-metilo-1-oxobutan-2-il}carbamato (Compuesto I) de fórmula (1) se prepararon y caracterizaron en el estado sólido. Se proporcionan además procesos de fabricación y métodos de uso de estas formas cristalinas, útiles para tratar la hepatitis C. Reivindicación 1: Metilo {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2 R)-2-[(metoxicarbonilo)amino]-2-fenilacetil}-4-(metoximetilo)pirrolidin-2-il]-1H-imidazol-5-il}-1,11-dihidroisocromeno[4,3:6,7]nafto[1,2-d]imidazol-2-il)-5-metilopirrolidin-1-il]-3-metilo-1-oxobutan-2-il}carbamato cristalino (Compuesto I Forma I) caracterizado por un difractograma de polvo de rayos X que comprende los siguientes picos: 4.8, 5.2, y 6.0º2q ± 0.2º2q, según lo determinado en un difractómetro usando radiación Cu-Ka a una longitud de onda de 1.5406 Å.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010919P | 2014-06-11 | 2014-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103194A1 true AR103194A1 (es) | 2017-04-26 |
Family
ID=53443009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101835A AR103194A1 (es) | 2014-06-11 | 2015-06-10 | Formas sólidas de un compuesto antiviral |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9630972B2 (es) |
| EP (3) | EP3822275A1 (es) |
| JP (3) | JP2017517532A (es) |
| KR (3) | KR20200145852A (es) |
| CN (1) | CN106661042A (es) |
| AR (1) | AR103194A1 (es) |
| AU (2) | AU2015274961A1 (es) |
| BR (1) | BR112016028843A2 (es) |
| CA (1) | CA2951188C (es) |
| EA (1) | EA201692220A1 (es) |
| ES (1) | ES2785409T3 (es) |
| IL (1) | IL249041A0 (es) |
| MX (1) | MX2016016299A (es) |
| PL (1) | PL3154983T3 (es) |
| PT (1) | PT3154983T (es) |
| SG (1) | SG11201609810YA (es) |
| SI (1) | SI3154983T1 (es) |
| TW (1) | TWI721947B (es) |
| WO (1) | WO2015191431A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3521297T3 (pl) | 2003-05-30 | 2022-04-04 | Gilead Pharmasset Llc | Zmodyfikowane fluorowane analogi nukleozydów |
| TWI548629B (zh) | 2010-11-17 | 2016-09-11 | 吉李德製藥公司 | 抗病毒化合物 |
| DK2907816T3 (en) | 2011-11-16 | 2018-09-24 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
| NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| CN108368123B (zh) * | 2016-07-08 | 2021-02-19 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑基化合物及其药物组合物 |
| CN106432253B (zh) * | 2016-09-21 | 2019-06-14 | 上海众强药业有限公司 | 一种维帕他韦新晶型及其制备方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CN1771245A (zh) | 2003-04-02 | 2006-05-10 | 安斯泰来制药有限公司 | 氟苯甲酰胺衍生物的新颖的晶体 |
| ES2456702T3 (es) | 2003-05-09 | 2014-04-23 | Boehringer Ingelheim International Gmbh | Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| RU2355691C2 (ru) * | 2004-09-22 | 2009-05-20 | Пфайзер Инк. | Полиморфные и аморфная формы фосфатной соли 8-фтор-2-{4-[(метиламино)метил]фенил}-1,3,4,5-тетрагидро-6н-азепино[5.4.3-cd]индол-6-она |
| EP2016052B1 (en) | 2006-05-05 | 2012-06-06 | Merck Patent GmbH | Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2009286694A (ja) | 2006-09-07 | 2009-12-10 | Eisai R & D Management Co Ltd | ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶 |
| CA2823981C (en) | 2006-12-07 | 2016-05-17 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2184282B1 (en) | 2007-08-10 | 2014-10-08 | Mitsubishi Tanabe Pharma Corporation | Novel salt of isoquinoline compound and crystal thereof |
| EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DK2242752T3 (da) | 2008-02-13 | 2012-11-19 | Bristol Myers Squibb Co | Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer |
| AR072991A1 (es) | 2008-08-07 | 2010-10-06 | Schering Corp | Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| WO2010065681A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| EA024853B1 (ru) | 2008-12-03 | 2016-10-31 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| AU2010229795A1 (en) | 2009-03-27 | 2011-10-13 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
| HRP20160476T1 (hr) | 2009-03-27 | 2016-06-03 | Merck Sharp & Dohme Corp. | Inhibitori replikacije virusa hepatitisa c |
| CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| JP2012526834A (ja) | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
| SI3309157T1 (sl) | 2009-05-13 | 2020-02-28 | Gilead Pharmasset Llc | Protivirusne spojine |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5795316B2 (ja) | 2009-09-04 | 2015-10-14 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 化合物 |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104341401B (zh) | 2009-12-18 | 2017-02-15 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| KR102163902B1 (ko) | 2010-09-21 | 2020-10-12 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제 |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| TWI548629B (zh) | 2010-11-17 | 2016-09-11 | 吉李德製藥公司 | 抗病毒化合物 |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| DK2907816T3 (en) | 2011-11-16 | 2018-09-24 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| CA2857339C (en) | 2011-12-29 | 2015-11-17 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| TW201434949A (zh) | 2013-01-31 | 2014-09-16 | Nitto Denko Corp | 環氧組合物及環氧樹脂成形體 |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
| EP3588013A1 (de) | 2018-06-26 | 2020-01-01 | XelectriX Power GmbH | Verfahren zur abgabe von elektrischer energie |
-
2015
- 2015-05-28 TW TW104117182A patent/TWI721947B/zh active
- 2015-06-08 JP JP2016572253A patent/JP2017517532A/ja not_active Withdrawn
- 2015-06-08 BR BR112016028843A patent/BR112016028843A2/pt not_active IP Right Cessation
- 2015-06-08 KR KR1020207036803A patent/KR20200145852A/ko not_active Ceased
- 2015-06-08 KR KR1020197001272A patent/KR20190007533A/ko not_active Ceased
- 2015-06-08 AU AU2015274961A patent/AU2015274961A1/en not_active Abandoned
- 2015-06-08 EA EA201692220A patent/EA201692220A1/ru unknown
- 2015-06-08 EP EP20213940.8A patent/EP3822275A1/en not_active Withdrawn
- 2015-06-08 CN CN201580031460.3A patent/CN106661042A/zh active Pending
- 2015-06-08 PT PT157306218T patent/PT3154983T/pt unknown
- 2015-06-08 ES ES15730621T patent/ES2785409T3/es active Active
- 2015-06-08 PL PL15730621T patent/PL3154983T3/pl unknown
- 2015-06-08 MX MX2016016299A patent/MX2016016299A/es unknown
- 2015-06-08 KR KR1020177000696A patent/KR20170015506A/ko not_active Ceased
- 2015-06-08 SI SI201531097T patent/SI3154983T1/sl unknown
- 2015-06-08 SG SG11201609810YA patent/SG11201609810YA/en unknown
- 2015-06-08 WO PCT/US2015/034649 patent/WO2015191431A1/en not_active Ceased
- 2015-06-08 EP EP20155444.1A patent/EP3666775A1/en not_active Withdrawn
- 2015-06-08 CA CA2951188A patent/CA2951188C/en active Active
- 2015-06-08 EP EP15730621.8A patent/EP3154983B1/en active Active
- 2015-06-08 US US14/733,101 patent/US9630972B2/en active Active
- 2015-06-10 AR ARP150101835A patent/AR103194A1/es unknown
-
2016
- 2016-11-17 IL IL249041A patent/IL249041A0/en unknown
-
2017
- 2017-03-15 US US15/459,785 patent/US9884873B2/en active Active
- 2017-12-18 US US15/845,837 patent/US10604530B2/en active Active
-
2018
- 2018-03-19 AU AU2018201948A patent/AU2018201948B2/en active Active
-
2019
- 2019-02-18 JP JP2019026534A patent/JP2019070057A/ja not_active Ceased
- 2019-07-19 JP JP2019133593A patent/JP2019172711A/ja active Pending
-
2020
- 2020-02-21 US US16/797,793 patent/US11203599B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103194A1 (es) | Formas sólidas de un compuesto antiviral | |
| AR096582A1 (es) | Procesos de fabricación y formas cristalinas de un inhibidor de mdm2 | |
| PE20170325A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll | |
| UA110259C2 (uk) | Похідні піролопіримідину і пурину | |
| CL2013002821A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor. | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| UY34261A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| BR112014030400A2 (pt) | formas sólidas de um composto antiviral | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| EA201591512A1 (ru) | Борсодержащие молекулы, способы и составы | |
| MX381341B (es) | Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirimidin-2(1h)-ona como fungicidas. | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| PE20201495A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| PE20151535A1 (es) | Derivado de dihidropiridazin-3,5-diona | |
| EA201591328A1 (ru) | Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний | |
| BR112013024965A2 (pt) | composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto | |
| CL2015000056A1 (es) | Compuestos derivados de carbamato/urea, inhibidores del receptor de histamina h3; procedimiento de preparación; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de narcolepsia. | |
| AR065714A1 (es) | Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida | |
| NI201800071A (es) | Compuestos de isoindol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |